Metabonomic understanding of probiotic effects in humans with irritable bowel syndrome

Journal of Clinical Gastroenterology

Volumn 45, Issue 5, 2011, Pages 415-425

  Hong, Young Shick ^a,b   Hong, Kyoung Sup ^c   Park, Min Hwa ^a   Ahn, Young Tae ^d   Lee, Jung Hee ^d   Huh, Chul Sung ^d   Lee, Jaekyung ^c   Kim, In Kyoung ^c   Hwang, Geum Sook ^a,e   Kim, Joo Sung ^c  

^a Korea Basic Science Institute (KBSI)   (South Korea)

^b Korea University   (South Korea)

^c Seoul National University Hospital   (South Korea)

^d Korea Yakult Co   (South Korea)

^e Chungnam National University   (South Korea)

Author keywords

IBS; metabolomics; metabonomics; NMR; Probiotics

Indexed keywords

GLUCOSE; LACTIC ACID; PLACEBO; PROBIOTIC AGENT; TYROSINE; YOGHURT;

ADULT; AMINO ACID BLOOD LEVEL; ARTICLE; BACTERIAL COUNT; BIFIDOBACTERIUM LONGUM; CONTROLLED STUDY; DOUBLE BLIND PROCEDURE; FEMALE; GENDER; GLUCOSE BLOOD LEVEL; HUMAN; IRRITABLE COLON; LACTATE BLOOD LEVEL; LACTOBACILLUS; LACTOBACILLUS BREVIS; MAJOR CLINICAL STUDY; MALE; METABOLOME; METABOLOMICS; PRIORITY JOURNAL; PROTON NUCLEAR MAGNETIC RESONANCE; RANDOMIZED CONTROLLED TRIAL; TREATMENT DURATION;

ADULT; BIFIDOBACTERIUM; DOUBLE-BLIND METHOD; FECES; FEMALE; HUMANS; IRRITABLE BOWEL SYNDROME; LACTOBACILLUS; MAGNETIC RESONANCE SPECTROSCOPY; MALE; METABOLOMICS; MIDDLE AGED; PROBIOTICS; QUESTIONNAIRES; TREATMENT OUTCOME; YOGURT; YOUNG ADULT;

EID: 79955018811     PISSN: 01920790     EISSN: None     Source Type: Journal    
DOI: 10.1097/MCG.0b013e318207f76c     Document Type: Article

References (51)

1. Talley NJ, Zinsmeister AR, Vandyke C, et al. Epidemiology of colonic symptoms and the irritable bowel syndrome. Gastroenterology. 1991;10:927-934.
2. Park KS, Ahn SH, Hwang JS, et al. A survey about irritable bowel syndrome in South Korea: prevalence and observable organic abnormalities in IBS patients. Dig Dis Sci. 2008;53: 704-711. (Pubitemid 351317084)
3. Isolauri E, Kirjavainen PV, Salminen S. Probiotics: a role in the treatment of intestinal infection and inflammation? Gut. 2002;50:54-59.
4. O'Mahony L, Feeney M, O'Halloran S, et al. Probiotic impact on microbial flora, inflammation and tumour development in IL-10 knockout mice. Aliment Pharmacol Ther. 2001;15:1219-2125.
5. Quigley EMM. Current concepts of the irritable bowel syndrome. Scand J Gastroenterol. 2003;38:1-8. (Pubitemid 36609870)
6. Balsari A, Ceccarelli A, Dubini F, et al. The fecal microbial population in the irritable bowel syndrome. Microbiologica. 1982;5:185-194. (Pubitemid 13228114)
7. Longstreth GF, Thompson WG, Chey WD, et al. Functional bowel disorders. Gastroenterology. 2006;130:1480-1491.
8. Williams HRT, Cox IJ, Walker DG, et al. Characterization of inflammatory bowel disease with urinary metabolic profiling. Am J Gastroenterol. 2009;104:1435-1444.
9. Marchesi JR, Holmes E, Khan F, et al. Rapid and noninvasive metabonomic characterization of inflammatory bowel disease. J Proteome Res. 2007;6:546-551. (Pubitemid 46340158)
10. Bertini I, Calalbro A, De Carli V, et al. The metabonomic signature of celiac disease. J Proteome Res. 2009;8:170-177.
11. Martin FPJ, Wang Y, Sprenger N, et al. Probiotic modulation of symbiotic gut microbial-host metabolic interactions in a humanized microbiome mouse model. Mol Syst Biol. 2008;4:157.
12. Martin FPJ, Dumas ME, Wang YL, et al. A top-down systems biology view of microbiome-mammalian metabolic interac-tions in a mouse model. Mol Syst Biol. 2008;3:112.
13. Lee HS, Han SY, Bae EA, et al. Lactic acid bacteria inhibit proinflammatory cytokine expression and bacterial glycosami-noglycan degradation activity in dextran sulfate sodium-induced colitic mice. Int Immunopharmacol. 2008;8:574-580.
14. Lee JH, Lee B, Lee HS, et al. Lactobacillus suntoryeus inhibits pro-inflammatory cytokine expression and TLR-4-linkded NF-kB activation in experimental colitis. Int J Colorectal Dis. 2009;24:231-237.
15. Heaton KW, Ghosh S, Braddon FE. How bad are the symptoms and bowel dysfunction of patients with the irritable bowel syndrome? A prospective, controlled study with emphasis on stool form. Gut. 1991;32:73-79.
16. Heaton KW, Radvan J, Cripps H, et al. Defecation frequency and timing, and stool form in the general population: a prospective study. Gut. 1992;33:231-237.
17. Saric J, Wang Y, Li J, et al. Species variation in the fecal metabolome gives insight into differential gastrointestinal function. J Proteome Res. 2008;7:352-360. (Pubitemid 351171149)
18. Saric J, Li JV, Wang Y, et al. Metabolic profiling of an Echinostoma caproni infection in the mouse for biomarker discovery. PLoS Negl Trop Dis. 2008;2:15.
19. Nicholson JK, Foxall PJ, Sprau M, et al. 750 MHz 1H and 1H-13C NMR spectroscopy of human blood plasma. Anal Chem. 1995;67:793-811.
20. Dieterle F, Ross A, Schlotterbeck G, et al. Probabilistic quotient normalization as robust method to account for dilution of complex biological mixtures: application in H-1 NMR metabonomics. Anal Chem. 2006;78:4281-4290.
21. Veselkov KA, Lindon JC, Ebbels TM, et al. Recursive segment-wise peak alignment of biological H-1 NMR spectra for improved metabolic biomarker recovery. Anal Chem. 2009;81:56-66.
22. Whelehan OP, Earll ME, Johansson E, et al. Detection of ovarian cancer using chemometric analysis of proteomic profiles. Chemon Intell Lab Syst. 2006;84:82-87. (Pubitemid 44780791)
23. Kirschenlohr HL, Griffin JL, Clarke SC, et al. Proton NMR analysis of plasma is a weak predictor of coronary artery disease. Nat Med. 2006;12:705-710. (Pubitemid 43865242)
24. Hodson MP, Dear GJ, Roberts AD, et al. A gender-specific discriminator in Sprague-Dawley rat urine: the deployment of a metabolic profiling strategy for biomarker discovery and identification. Anal Biochem. 2007;362:182-192. (Pubitemid 46227324)
25. Stanley EG, Bailey NJC, Bollard ME, et al. Sexual dimorph-ism in urinary metabolite profiles of Han Wistar rats revealed by nuclear-magnetic-resonance- based metabonomics. Anal Biochem. 2005;343:195-202. (Pubitemid 41074031)
26. Bollard ME, Stanley EG, Lindon JC, et al. NMR-based metabonomic approaches for evaluating physiological influences on biofluid composition. NMR Biomed. 2005;18:143-162. (Pubitemid 40716122)
27. Slupsky CM, Rankin KN, Wagner J, et al. Investigations of the effects of gender, diurnal variation, and age in human urinary metabolomic profiles. Anal Chem. 2007;79: 6995-7004. (Pubitemid 47438678)
28. Psihogios NG, Gazi IF, Elisaf MS, et al. Gender-related and age-related urinalysis of healthy subjects by NMR-based metabonomics. NMR Biomed. 2008;21:195-207. (Pubitemid 351513667)
29. van Velzen EJ, Westerhuis JA, van Duynhoven JP, et al. Multilevel data analysis of a crossover designed human nutritional intervention study. J Proteome Res. 2008;7:4483-4491.
30. Kochhar S, Jacobs DM, Ramadan Z, et al. Probing gender-specific metabolism differences in humans by nuclear magnetic resonance-based metabonomics. Anal Biochem. 2006;352: 274-281.
31. Ueda R, Shimada M, Hashimoto H, et al. Distinct regulation of two hydroxysteroid sulfotransferases, ST2A1 and ST2A2, by growth hormone: a unique type of growth hormone regulation in rats. JPharmacol Exp Ther. 1997;282:1117-1121. (Pubitemid 27340219)
32. Joossens JV. Mechanisms of hypercholesterolemia and athero-sclerosis. Acta Cardiol Suppl. 1998;29:63-83.
33. Eriksson L, Trygg J, Wold S. CV-ANOVA for significance testing of PLS and OPLS (R) models. J Chemometr. 2008;22: 594-600.
34. Lindgren F, Hansen B, Karcher W, et al. Model validation by permutation tests: applications to variable selection. J Chemometr. 1998;10:521-532.
35. Hove H, Nordgaard-Andersen I, Mortensen PB. Fecal DL-lactate concentration in 100 gastrointestinal patients. Scand J Gastroenterol. 1994;29:255-259. (Pubitemid 24103000)
36. Kaneko T, Bando Y, Kurihara H, et al. Fecal microflora in a patient with short-bowel syndrome and identification of dominant lactobacilli. J Clin Microbiol. 1997;35:3181-3185. (Pubitemid 27505741)
37. Thwaites DT, Anderson CMH. H +-coupled nutrient, micro-nutrient and drug transports in the mammalian small intestine. Exp Physiol. 2007;92:603-619. (Pubitemid 47024940)
38. Koskova I, Petrasek R, Vondra K, et al. Metabolic profile and sex hormone binding globulin (SHBG) in different reproduc-tive phases of Czech women and their relations to weight, body composition and fat distribution. Physiol Res. 2009;58: 393-402.
39. West J, Logan RF, Hill PG, et al. The iceberg of celiac disease: What is below the waterline? Clin Gastroenterol Hepatol. 2007;5:59-62. (Pubitemid 46096839)
40. Martin FPJ, Ressi S, Montoliu I, et al. Metabolic assessment of gradual development of moderate experimental colitis in IL-10 deficient mice. J Proteome Res. 2009;8:2376-2387.
41. Levine RJ, Conn HO. Tyrosine metabolism in patients with liver disease. J Clin Invest. 1967;46:2012-2020.
42. Coen M, Hong YS, Clayton TA, et al. The mechanism of galactosamine toxicity revisited; a metabonomic study. J Proteome Res. 2007;6:2711-2719. (Pubitemid 47122366)
43. Clayton TA, Lindon JC, Everett JR, et al. Hepatotoxin-induced hypertyrosinemia and its toxicological significance. Arch Toxicol. 2007;81:201-210. (Pubitemid 46364902)
44. Greenstin AJ, Janowitz HD, Sachar DB. The extra-intestinal complications of Crohn's disease and ulcerative colitis: a study of700 patients. Medicine. 1976;55:401-412.
45. Wewer V, Gluud C, Schlichting P, et al. Prevalence of hepatobiliary dysfunction in a regional group of patients with chronic inflammatory bowel disease. Scand J Gastroenterol. 1991;26:97-102.
46. Broome U, Glaumann H, Hellers G, et al. Liver disease in ulcerative colitis: an epidemiological and follow up study in the country of Stockholm. Gut. 1994;35:84-89. (Pubitemid 24059478)
47. Gisbert JP, Luna M, Gonzaiez-Lama Y, et al. Liver injury in inflammatory bowel disease: long-term follow-up study of 786 patients. Inflamm Bowel Dis. 2007;13:1106-1114. (Pubitemid 47402594)
48. Gratz SW, Mykkanen H, El-Nezami HS. Probiotics and gut health: a special focus on liver disease. World J Gastroenterol. 2010;16:403-410.
49. Loguercio C, De Simone T, Federico A, et al. Gut-liver axis: a new point of attack to treat chronic liver damage? Am J Gastroenterol. 2002;97:2144-2146.
50. Sheth AA, Garcia-Tsao G. Probiotics and liver disease. J Clin Gastroenterol. 2008;42(suppl 2):S80-S84.
51. McClay JL, Adkins DE, Isern NG, et al. 1H nuclear magnetic resonance metabolomics analysis identifies novel urinary biomarkers for lung function. J Proteome Res. 2010;9: 3083-3090.